1 / 18

Development and Evaluation of Software for MDR-TB Treatment in Peru

This study aims to develop and evaluate a web-based electronic medical record system to assist in drug prescribing and supply management for MDR-TB treatment in Peru. The system enables accurate record keeping, data analysis, and prediction of drug requirements.

fgallion
Download Presentation

Development and Evaluation of Software for MDR-TB Treatment in Peru

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Development and evaluation of software to support prescribing and drug supply management in the treatment of MDR-TB in Peru. Fraser H, Choi S, Jazayeri D, Kempton K, Bayona J Partners In Health & Harvard Medical School, Boston, USA

  2. Introduction Problem Statement: Multi-drug resistant tuberculosis (MDR-TB) is a major problem in many developing countries, and treatment requires complex and expensive drug regimens. Optimal drug regimens improve outcomes and reduce costs. Ensuring that drugs are ordered correctly at the lowest price, and avoiding stock-outs, requires excellent record keeping and data analysis. Objectives: To develop and evaluate a web-based electronic medical record system (EMR) to assist in drug prescribing and drug supply management. Setting: A national community-based treatment program for MDR-TB in Peru. Over 100 public health centers, mainly in Lima, participated, starting in February, 1999 with 75 patients. Study Population: 1590 patients who received treatment for MDR-TB from February 1, 1999 until November 2003. 370 patient records in two districts were studied for the drug data entrystudy.

  3. The PIH-EMR • A secure (SSL) web based electronic medical record for MDR-TB using a relational database • Usable over low-speed Internet connections • Bilingual: English/Spanish • Extensive data analysis tools • Uses: • Clinical care, patient summaries, laboratory data • Monthly reports on patient outcomes • Drug supply management • Ordering and tracking laboratory results • Research studies

  4. Evaluation studies Software was developed in housein close collaboration with the medical and nursing staff in Lima, Peru. Evaluation was performed of two aspects of the system in use: 1) the accuracy of the analysis programs for predicting future drug requirements compared with actual usage. 2) The entry of medication regimens directly into the electronic medical record(EMR) by the nurses assessed by comparing one intervention and one control district

  5. Prediction of drug requirements (morbidity) One months medication for MDR-TB Drug regimen entry form Analysis of 1 months drug requirements from integration of all medication regimens

  6. Predicted versus actual drug usage from drug regimens in PIH-EMR • We compared the predicted usage from drug regimens to actual usage in the warehouse • Warehouse usage requires to be averaged over at least 4 months due to variability • Usage was also estimated from a 1 day snapshot of drug regimens compared to 3 month integration of regimen data (1) Predicted use is affected by enrollment rate, time in treatment and changes in preferred medications

  7. Regimen estimate vs. usage for 2002-2003 * * * Note discrepancies for 2 types of PAS cancel 1592 patients, 24 months data, over 6 Million doses included

  8. 3 month estimates from one day snap-shot of regimens (1 Jan 02 – 31 Mar 02)

  9. MDR-TB Patient enrollments Sep. 1996 - Mar. 2004 (per 30 days)

  10. Time patients remain in treatment (Aug-03)

  11. Changes in total quinolone usage 2002 – 2003Overall quinolone use is stable but substitutions complicate assessment

  12. Collection of accurate medication data • Drug regimens must be accurately recorded and updated to ensure reliable estimates • Data entry may be from paper forms/charts or by medical staff or nurses • Checks are required to ensure that the data is accurate and complete • Data integrity checks eg. overlapping prescriptions • Cross checks with other records e.g. pharmacy

  13. Direct order entry of medications • Nurses manage the medications for patients (once the pulmonologist has decided on the regimen) • Initially we identified problems with data accuracy in drug regimens • We developed: • a custom prescription form for the doctors • a web-based drug order entry system for nurses

  14. Nurse order entry forms

  15. Evaluation of drug data accuracy • Quality and timeliness of the drug regimen data in the EMR was surveyed in Nov. /Dec. 2002 • 90 charts in Callao – intervention site • 77 charts Lima Este- control site • Data entry in Callao commenced 10th Feb. 2003 • Survey was repeated early April 2003 • 95 charts Callao (80 same as initial review) • 102 charts Este (71 same as initial review)

  16. Drug data accuracy: results:Percentage of medication in errors in EMR per patient. Most errors were delays in updating regimens. Date/SiteCallao Lima Este active control December 02 17.4%* 8.6%** April 03 3.1%* 6.9%** *P= 0.0075 **P= 0.66, Wilcoxon signed-rank test

  17. Conclusions: • The web based EMR can permit order entry in a developing country and improve the quality of drug regimen data. • Regimen data can be used to predict drug requirements, and hence improve drug procurement. • Comparing predicted and actual drug use allows errors or discrepancies in data to be detected (such as incorrect number of doses from a new form of PAS). • Predictions of future drug use requires knowledge of: • changes in enrollment rate • length of time in treatment • Changes in drug use for clinical or programmatic reasons

More Related